Why the study?
Surgical options for tricuspid regurgitation are often complicated by significant morbidity and mortality in elderly patients with multiple comorbidities, creating a gap in therapeutic options.
This review provides a comprehensive overview of the rapidly evolving field of transcatheter tricuspid valve interventions, highlighting the various device strategies and their early clinical promise for treating tricuspid regurgitation.
Answers are grounded in this paper and cite their sources.
TTVI may expand options for high-risk TR patients; leaves open questions on long-term outcomes and selection.
Tricuspid regurgitation (TR) adversely impacts both quality of life and long-term survival, which generates interest in therapeutic approaches to mitigate these effects. Historically, therapeutic options for TR were limited to surgical approaches, which are often complicated by significant morbidity and mortality in elderly patients with multiple comorbidities. This gap in therapeutic options led to the rapid evolution of transcatheter tricuspid valve intervention (TTVI), with a wide variety of approaches pursued and early results suggesting that TTVI improves clinical outcomes. Numerous strategies, including edge-to-edge repair, annular reduction, spacers, caval valve implantation, and transcatheter tricuspid valve replacement form the basis of TTVI today. In this review, the authors discuss the current state of each approach.
No takes yet. Share an insight, caveat, or question.
Simard et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: